COMPANY
Catalyst Pharmaceuticals
Timeline
- Trial start —: Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT source ↗
- Trial start Phase 2: Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3 source ↗
- Trial start Phase 2: Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients source ↗
- Trial start Phase 3: Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis) source ↗
- Trial start Phase 3: Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG source ↗
- Trial start 3: Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) source ↗
- Trial start Phase 3: Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes source ↗
- Trial start Phase 1: A Safety, Tolerability and Pharmacokinetic Study of CPP-115 source ↗
- Trial start 3: A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) source ↗
- Trial start Phase 2/Phase 3: Vigabatrin for the Treatment of Cocaine Dependency source ↗
- Trial start Phase 2: Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence source ↗
- Trial start Phase 2: Vigabatrin for Treatment of Cocaine Dependence source ↗
Upcoming milestones
- 2032-02 (ESTIMATED) · · Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT · NCT06564974
Clinical trials (lead sponsor) 13
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06564974 | Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT | Not listed | Recruiting | Sep 25, 2024 | 2032-02 (estimated) |
| NCT02189720 | Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome | Not listed | Approved for marketing | Not listed | Not listed |
| NCT03579966 | Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis) | Phase 3 | Terminated | Jun 11, 2018 | Aug 5, 2022 (actual) |
| NCT03304054 | Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG | Phase 3 | Completed | Apr 18, 2018 | Jan 31, 2020 (actual) |
| NCT03819660 | Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3 | Phase 2 | Terminated | Mar 7, 2019 | Sep 13, 2021 (actual) |
| NCT03781479 | Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients | Phase 2 | Completed | Jan 21, 2019 | Jul 23, 2020 (actual) |
| NCT01493596 | A Safety, Tolerability and Pharmacokinetic Study of CPP-115 | Phase 1 | Completed | 2011-12 | 2012-06 (actual) |
| NCT02562066 | Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes | Phase 3 | Completed | 2016-01 | 2019-08 (actual) |
| NCT00730522 | Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence | Phase 2 | Terminated | 2008-07 | 2009-06 (actual) |
| NCT02970162 | Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) | 3 | Completed | 2016-11 | 2017-10 (actual) |
| NCT01377922 | A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) | 3 | Completed | 2011-06 | 2016-07 (actual) |
| NCT01281202 | Vigabatrin for the Treatment of Cocaine Dependency | Phase 2/Phase 3 | Completed | 2011-01 | 2012-10 (actual) |
| NCT00611130 | Vigabatrin for Treatment of Cocaine Dependence | Phase 2 | Completed | 2008-01 | 2009-05 (actual) |
Connect
See your connections at Catalyst Pharmaceuticals on LinkedIn (search by name, results not checked)